An Australian firm has got the green light from the European Medicines Agency to start Phase 2 clinical trials in Europe for its stem-cell-based drug Revascor. Melbourne-based Mesoblast will assess the safety and efficacy of Revascor, designed to treat cardiovascular disease, in 225 patients at sites in the UK, the Netherlands and Belgium.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.